.@Dysautonomia President Lauren Stiles and other patient advocates are quoted in this article exploring what the @NIH has done with $1.15B in US taxpayer funds allocated to #LongCOVID research. 1/🧵
Dysautonomia International advocates serve on several RECOVER committees & have been fighting hard to get the NIH to spend these funds on research that is urgently needed to develop more effective treatments for people with #LongCOVID (a majority of whom have #dysautonomia). 2/🧵
While there are some great people involved with RECOVER, RECOVER as a whole has failed to deliver & is hampered by excessive bureaucracy, lack of accountability for decision making, and NIH's failure to put experienced post-viral illness researchers in leadership roles. 3/🧵
We have been on multiple calls to vote on autonomic testing since 2021. Each committee recommends it, the vote is ignored by leadership, autonomic testing is not implemented, and as a result, RECOVER failed to capture any meaningful data on autonomic dysfunction to date. 4/🧵
Why is that a problem? Because research outside of RECOVER shows that about 70% of Long COVID patients have dysautonomia, and pre-COVID research shows that dysautonomia drives fatigue, brain fog, exercise intolerance, immune dysfunction, sleep problems and more. 5/🧵
We need RECOVER to implement the full COMPASS-31 and 10 min active stand test on ALL RECOVER subjects NOW. We need complete autonomic function testing, plus catecholamines and skin biopsy, in a large study of controls and PASC patients NOW. 6/🧵
We need clinical trials exploring treatments to improve autonomic function NOW: IVIG, PLEX, pulse steroids, other immune modulators, ivabradine, vagus nerve stim, Mestinon, etc. There are SO many options, but patients are being denied access because there are no trials. 7/🧵
If RECOVER isn't going to take timely action, we need other sources of research funding. Join us in calling on Congress & @NIH to fund $50M in #POTS research. Take action at bit.ly/FundPOTS The POTS population has doubled since 2020 as a result of #LongCOVID. end/🧵
• • •
Missing some Tweet in this thread? You can try to
force a refresh
@TODAYshow@ahandvanish@patientled said "the good news is that many POTS patients recover, but it can take years." Unfortunately, the two longest & largest studies to date suggest that a majority of POTS patients do NOT fully recover, but many patients do see partial improvement in symptoms with treatment. 2/🧵
A survey of 172 adolescent onset POTS patients who had been seen at Mayo Clinic, an average of about 5 years after their diagnosis, found that only 19% of patients reported "recovery." 3/🧵 pubmed.ncbi.nlm.nih.gov/26979650/
Important new #POTS research from Karolinska Inst. funded by Dysautonomia International has found biomarkers associated with a hypercoagulable & proinflammatory state, enhanced cardiac contractility & hypertrophy, skeletal muscle deficits, cartilage protein deficits & more. 1/🧵
The researchers used mass spectrometry to analyze proteins in the plasma of 65 #POTS & 65 healthy folks. They found >20 dysregulated proteins in POTS, then looked at how those proteins relate to each other in different pathways. All of this plasma was collected before COVID. 2/🧵
The strongest network interactions in #POTS were associated with a hypercoagulable state - upregulated expression of proteins related to platelet aggregation and activation. Small prior studies found increased rates of blood clots in POTS. 3/🧵
Important new case series from @dysclinic reporting outcomes in 7 #POTS patients who received SCIG and/or PLEX immunotherapy. A thread... 🧵⬇️
These patients had severe POTS that didn't respond well to standard treatments. All of the patients reported significant improvement in their dysautonomia symptoms and their ability to function after SCIG and/or PLEX.
Notably, 4 of the 7 patients also had #EDS and #MCAS, and their symptoms improved as well on immunotherapy. None of the patients in the case series had adverse events from the immunotherapy. Read the abstract: link.springer.com/article/10.100….
A team of researchers from NIH, Harvard, Johns Hopkins & Mt. Sinai just published a case series on 23 previously healthy individuals who developed #POTS or other neurological problems within 1 month after receiving a #COVID vaccine. Let's dig in: 🧵
They found autonomic dysfunction, small fiber neuropathy, inflammation of small fiber nerves, and that immune proteins called complement were being deposited on the small fiber nerves, which is seen in some autoimmune neurological disorders. 🧵
They emphasize that their study does NOT conclusively confirm that COVID vaccines caused the neurological illness, but circumstantial evidence suggests immune dysregulation is likely involved. They call for further research to understand mechanisms and clinical trials. 🧵
🔥Hot off the press!🔥 New POTS research suggesting #POTS might be a mixed autoinflammatory/autoimmune condition from Dr. Grubb & Dr. Gunning at University of Toledo. Get ready for a thread...🧵👇
Comparing 35 POTS patients to 35 non-POTS patients, they found that POTS patients had significantly elevated cytokines and chemokines:
CD30
interleukin-1 beta
interleukin-6
interleukin-10
interleukin-17
interleukin-18
interleukin-21
interferon-gamma
MCP1(CCL2)
RANTES (CCL5)
They also found decreased levels of interferon-alpha & that all 35 POTS patients had platelet delta granule storage pool deficiency, which they believe is a result of chronic inflammation. Read the full article to learn more about these findings: mdpi.com/2073-4409/11/5….
New research on small fiber neuropathy and dysautonomia in hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorder (HSD)! Read our 🧵👇 for details.
Researchers in Switzerland screened 79 hEDS/HSD patients who had dysautonomia or neuropathic pain for small fiber neuropathy (sensory small fiber neuropathy can cause pain, numbness, tingling, and itching; autonomic small fiber neuropathy can cause dysautonomia).
The researchers found definite small fiber neuropathy in 58% of hEDS/HSD patients & possible small fiber neuropathy in 33% of hEDS/HSD patients. There were no significant differences in any of the symptoms, quality of life, psych or small fiber nerve density between hEDS and HSD.